Point Of Care Testing Market Size Share Competitive Landscape And Trend Analysis Report Report
RA00539
Point of Care Testing Market Size, Share, Competitive Landscape, and Trend Analysis Report by Product Type, Platform, Mode of Purchase, Testing Type, End User, and Region: Global Opportunity Analysis and Industry Forecast, 2024-2033
The point of care testing market was valued at $45,911.25 million in 2023 and is estimated to reach $152,015.06 million by 2033 exhibiting a CAGR of 12.7% from 2024 to 2033
Market Introduction and Definition
Point-of-care testing (POCT) refers to medical diagnostic testing performed outside of a traditional laboratory setting, typically at or near the site of patient care. It enables rapid and convenient testing to support immediate clinical decision-making. POCT devices are designed to be portable and easy to use, allowing testing to be performed in various healthcare settings, such as clinics, doctor's offices, emergency rooms, or even at home.
POCT eliminates the need for sending samples to a centralized laboratory, reducing the turnaround time for results, and enabling faster interventions. POCT devices are available for a wide range of diagnostic tests, including blood glucose monitoring, infectious disease testing (like flu or COVID-19), coagulation testing, cardiac markers, and more. POCT devices are increasingly being designed to integrate with electronic health records (EHRs) and other healthcare information systems, facilitating seamless data management and continuity of care.
Key Takeaways
- The point of care testing market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($million) for the projected period from 2024 to 2033.
- More than 1,500 product literatures, industry releases, annual reports, and other such documents of major energy storage system industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
Industry Trends
- In July 2023, Vital Biosciences introduced VitalOne, an innovative point-of-care laboratory testing platform that enables widespread blood testing. This technology allows doctors to perform tests, diagnose, and treat patients all in one visit.
- In February 2023, Huwel Lifesciences developed a portable RT-PCR machine for virus testing. According to the company, this test can identify various infections, including respiratory ailments, using blood and gastrointestinal samples within approximately 30 minutes.
- In January 2023, India-based pharmaceutical company Cipla Limited introduced Cippoint, a point-of-care testing device capable of assessing various health parameters including diabetes, cardiac markers, fertility, infectious diseases, inflammation, thyroid function, coagulation markers, and metabolic indicators.
- In March 2023, F. Hoffman-La Roche Ltd formed a strategic partnership with Eli Lilly to collaborate on advancing the Elecsys Amyloid Plasma Panel (EAPP). This alliance aims to address a significant area of unmet medical needs by enhancing patient pathways from diagnosis through to treatment and treatment management, benefiting both companies involved.
Key Market Dynamics
POCT is expanding beyond hospitals and clinics into non-traditional settings such as pharmacies, ambulatory care settings, and even homes. This decentralization of testing services enhances accessibility and convenience for patients. The prevalence of chronic diseases like diabetes, cardiovascular diseases, and infectious diseases has fueled the demand for POCT outside traditional healthcare settings. For instance, diabetes management often requires frequent testing of blood glucose levels, which can be more accessible through point-of-care devices available in pharmacies or at home. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million people in the U.S. had diabetes in 2020. Moreover, governments and healthcare regulatory bodies are increasingly supportive of POCT in non-traditional settings due to its potential to improve patient outcomes and reduce healthcare costs. For example, the U.S. Centers for Medicare & Medicaid Services (CMS) has expanded coverage for certain POCT services provided outside of traditional settings. These factors are predicted to drive the point of care testing market growth during the forecast period.
POCT devices and assays are manufactured by different companies with varying processes and technologies. This can lead to variability in the quality and performance of these devices. Ensuring consistent quality across different batches and manufacturers is essential but challenging. Setting and adhering to performance standards for POCT devices can be complex due to the diversity of technologies and tests involved. Harmonizing these standards across different regions and healthcare settings is crucial for reliable and accurate results. These factors are anticipated to restrain the point of care testing market growth during the forecast period.
Growing investments by healthcare companies and venture capital firms in POCT technologies are significantly impacting the market landscape. The surge in financial support is accelerating the advancement of POCT solutions, driving improvements in efficiency, accuracy, and accessibility of diagnostic tools at the point of care. As a result, the market is experiencing a rapid expansion of capabilities and offerings, opening new avenues for growth and adoption across various healthcare settings. These factors are anticipated to create opportunities in the point of care testing market during the forecast years.
Socio Economic Impact Analysis in the Global Point of Care Testing Market
Improved Patient Outcomes: POCT enables quicker diagnosis and treatment decisions, leading to improved patient outcomes. For instance, in emergency situations like heart attacks or strokes, rapid testing for cardiac markers or clotting factors can significantly reduce morbidity and mortality rates.
Increased Efficiency: POCT streamlines the diagnostic process, eliminating the need for sample transportation and centralized laboratory processing. This not only saves time but also reduces the burden on laboratory resources, allowing them to focus on more complex testing and research activities.
Market Segmentation
The point of care testing market is segmented into product type, platform, mode of purchase, testing type, end user, and region. On the basis of product type, the market is divided into COVID-19 testing kits, glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy and fertility testing products, pregnancy testing products, fertility testing products, cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, fecal occult testing products, and others. As per platform, the market is segregated into lateral flow assays, dipsticks, microfluids, molecular diagnostics and immunoassays. On the mode of purchase, the market is OTC products, and prescribed based products. On the basis of testing type, the market is immunoassays, cell-based assays, nucleic acid amplification testing, clinical chemistry assays, and hematology. On the basis of end user, the market is clinical laboratories, ambulatory care facilities and physician offices, pharmacies, retail clinics & E-comm platforms, hospitals, critical care centers, urgent care centers, home care & self-testing, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional Market Outlook
Increasing incidence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases is a significant driver for POCT adoption. Chronic diseases account for a substantial portion of healthcare expenditure in the U.S., driving the need for efficient and rapid diagnostic tools. In the U.S. healthcare system, there is a growing demand for rapid diagnostic tools that can provide immediate results to aid in timely decision-making by healthcare professionals. This demand is evidenced by the increasing adoption rates of POCT devices across various healthcare settings. The growth of investment in healthcare technology research and development reflects the increasing interest and support for innovative POCT solutions.
On April 27, 2023, Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, announced the completion of its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers for the combined company. In addition, significant operational synergies are anticipated in procurement, R&D logistics and production.
Competitive Landscape
The major players operating in the point of care testing market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Johnson & Johnson, Danaher Corporation, Becton, Dickinson and Company (BD), Philips Healthcare, Sysmex Corporation, Quidel Corporation, and Chembio Diagnostics.
Recent Key Strategies and Developments
- On 13 February 2024, Roche entered into a collaboration agreement with PathAI to expand its digital pathology capabilities for companion diagnostics. Roche Diagnostics continued to expand its POCT capabilities through strategic acquisitions and collaborations.
- On 24 December 2021, Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its COVID-19 At-Home Test. The test uses a simple anterior nasal swab sample that can be conveniently self-collected and self-tested by individuals aged 14 years and older, and by an adult for children aged 2-13 years old. The test is able to produce accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron.
Key Sources Referred
- Food and Drug Administration (FDA)
- Clinical and Laboratory Standards Institute (CLSI)
- Centers for Disease Control and Prevention (CDC)
- World Health Organization (WHO)
- American Association for Clinical Chemistry (AACC)
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the point of care testing market segments, current trends, estimations, and dynamics of the point of care testing market analysis from 2024 to 2033 to identify the prevailing point of care testing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the point of care testing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global point of care testing market Statistics.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
Apart from the points mentioned above, the report includes the analysis of the regional as well as global point of care testing trends, key players, market segments, application areas, and market growth strategies.
| Aspect | Particulars |
| Historical Market Estimations | 2021-2022 |
| Base Year for Market Estimation | 2023 |
| Forecast Timeline for Market Projection | 2024-2033 |
| Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
| Segmentation by Product Type |
|
| Segmentation by Platform |
|
| Segmentation by Mode of Purchase |
|
| Segmentation by Testing Type |
|
| Segmentation by End User |
|
| Key Companies Profiled |
|
1. Research Methodology
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
2. Report Scope
2.1. Market definition
2.2. Key objectives of the study
2.3. Market segmentation
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive Rivalry Intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Legal
4.6.6. Environmental
4.7. Impact of COVID-19 on Point Of Care Testing Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
5. Point Of Care Testing Market Analysis, by Product Type
5.1. Overview
5.2. COVID-19 testing kits
5.2.1. Definition, key trends, growth factors, and opportunities
5.2.2. Market size analysis, by region, 2022-2032
5.2.3. Market share analysis, by country, 2022-2032
5.3. Glucose Monitoring Products
5.3.1. Definition, key trends, growth factors, and opportunities
5.3.2. Market size analysis, by region, 2022-2032
5.3.3. Market share analysis, by country, 2022-2032
5.4. Cardiometabolic Monitoring Products
5.4.1. Definition, key trends, growth factors, and opportunities
5.4.2. Market size analysis, by region, 2022-2032
5.4.3. Market share analysis, by country, 2022-2032
5.5. Infectious Disease Testing Products
5.5.1. Definition, key trends, growth factors, and opportunities
5.5.2. Market size analysis, by region, 2022-2032
5.5.3. Market share analysis, by country, 2022-2032
5.6. Coagulation Monitoring Products
5.6.1. Definition, key trends, growth factors, and opportunities
5.6.2. Market size analysis, by region, 2022-2032
5.6.3. Market share analysis, by country, 2022-2032
5.7. Pregnancy And Fertility Testing Products
5.7.1. Definition, key trends, growth factors, and opportunities
5.7.2. Market size analysis, by region, 2022-2032
5.7.3. Market share analysis, by country, 2022-2032
5.8. Pregnancy Testing Products
5.8.1. Definition, key trends, growth factors, and opportunities
5.8.2. Market size analysis, by region, 2022-2032
5.8.3. Market share analysis, by country, 2022-2032
5.9. Fertility Testing Products
5.9.1. Definition, key trends, growth factors, and opportunities
5.9.2. Market size analysis, by region, 2022-2032
5.9.3. Market share analysis, by country, 2022-2032
5.10. Cancer Marker Testing Products
5.10.1. Definition, key trends, growth factors, and opportunities
5.10.2. Market size analysis, by region, 2022-2032
5.10.3. Market share analysis, by country, 2022-2032
5.11. Urinalysis Testing Products
5.11.1. Definition, key trends, growth factors, and opportunities
5.11.2. Market size analysis, by region, 2022-2032
5.11.3. Market share analysis, by country, 2022-2032
5.12. Cholesterol Testing Products
5.12.1. Definition, key trends, growth factors, and opportunities
5.12.2. Market size analysis, by region, 2022-2032
5.12.3. Market share analysis, by country, 2022-2032
5.13. Hematology Testing Products
5.13.1. Definition, key trends, growth factors, and opportunities
5.13.2. Market size analysis, by region, 2022-2032
5.13.3. Market share analysis, by country, 2022-2032
5.14. Drugs-Of-Abuse Testing Products
5.14.1. Definition, key trends, growth factors, and opportunities
5.14.2. Market size analysis, by region, 2022-2032
5.14.3. Market share analysis, by country, 2022-2032
5.15. Fecal Occult Testing Products
5.15.1. Definition, key trends, growth factors, and opportunities
5.15.2. Market size analysis, by region, 2022-2032
5.15.3. Market share analysis, by country, 2022-2032
5.16. Others
5.16.1. Definition, key trends, growth factors, and opportunities
5.16.2. Market size analysis, by region, 2022-2032
5.16.3. Market share analysis, by country, 2022-2032
5.17. Research Dive Exclusive Insights
5.17.1. Market attractiveness
5.17.2. Competition heatmap
6. Point Of Care Testing Market Analysis, by Platform
6.1. Overview
6.2. Lateral Flow Assays
6.2.1. Definition, key trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2022-2032
6.2.3. Market share analysis, by country, 2022-2032
6.3. Dipsticks
6.3.1. Definition, key trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2022-2032
6.3.3. Market share analysis, by country, 2022-2032
6.4. Microfluids
6.4.1. Definition, key trends, growth factors, and opportunities
6.4.2. Market size analysis, by region, 2022-2032
6.4.3. Market share analysis, by country, 2022-2032
6.5. Molecular Diagnostics and Immunoassays
6.5.1. Definition, key trends, growth factors, and opportunities
6.5.2. Market size analysis, by region, 2022-2032
6.5.3. Market share analysis, by country, 2022-2032
6.6. Research Dive Exclusive Insights
6.6.1. Market attractiveness
6.6.2. Competition heatmap
7. Point Of Care Testing Market Analysis, by Mode of Purchase
7.1. Overview
7.2. OTC Products
7.2.1. Definition, key trends, growth factors, and opportunities
7.2.2. Market size analysis, by region, 2022-2032
7.2.3. Market share analysis, by country, 2022-2032
7.3. Prescribed Based Products
7.3.1. Definition, key trends, growth factors, and opportunities
7.3.2. Market size analysis, by region, 2022-2032
7.3.3. Market share analysis, by country, 2022-2032
7.4. Research Dive Exclusive Insights
7.4.1. Market attractiveness
7.4.2. Competition heatmap
8. Point Of Care Testing Market Analysis, by Testing Type
8.1. Overview
8.2. Immunoassays
8.2.1. Definition, key trends, growth factors, and opportunities
8.2.2. Market size analysis, by region, 2022-2032
8.2.3. Market share analysis, by country, 2022-2032
8.3. Cell-Based Assays
8.3.1. Definition, key trends, growth factors, and opportunities
8.3.2. Market size analysis, by region, 2022-2032
8.3.3. Market share analysis, by country, 2022-2032
8.4. Nucleic Acid Amplification Testing
8.4.1. Definition, key trends, growth factors, and opportunities
8.4.2. Market size analysis, by region, 2022-2032
8.4.3. Market share analysis, by country, 2022-2032
8.5. Clinical Chemistry Assays
8.5.1. Definition, key trends, growth factors, and opportunities
8.5.2. Market size analysis, by region, 2022-2032
8.5.3. Market share analysis, by country, 2022-2032
8.6. Hematology
8.6.1. Definition, key trends, growth factors, and opportunities
8.6.2. Market size analysis, by region, 2022-2032
8.6.3. Market share analysis, by country, 2022-2032
8.7. Research Dive Exclusive Insights
8.7.1. Market attractiveness
8.7.2. Competition heatmap
9. Point Of Care Testing Market Analysis, by End-use
9.1. Overview
9.2. Clinical Laboratories
9.2.1. Definition, key trends, growth factors, and opportunities
9.2.2. Market size analysis, by region, 2022-2032
9.2.3. Market share analysis, by country, 2022-2032
9.3. Ambulatory Care Facilities and Physician Offices
9.3.1. Definition, key trends, growth factors, and opportunities
9.3.2. Market size analysis, by region, 2022-2032
9.3.3. Market share analysis, by country, 2022-2032
9.4. Pharmacies
9.4.1. Definition, key trends, growth factors, and opportunities
9.4.2. Market size analysis, by region, 2022-2032
9.4.3. Market share analysis, by country, 2022-2032
9.5. Retail Clinics & E-Comm Platforms
9.5.1. Definition, key trends, growth factors, and opportunities
9.5.2. Market size analysis, by region, 2022-2032
9.5.3. Market share analysis, by country, 2022-2032
9.6. Hospitals
9.6.1. Definition, key trends, growth factors, and opportunities
9.6.2. Market size analysis, by region, 2022-2032
9.6.3. Market share analysis, by country, 2022-2032
9.7. Critical Care Centers
9.7.1. Definition, key trends, growth factors, and opportunities
9.7.2. Market size analysis, by region, 2022-2032
9.7.3. Market share analysis, by country, 2022-2032
9.8. Urgent Care Centers
9.8.1. Definition, key trends, growth factors, and opportunities
9.8.2. Market size analysis, by region, 2022-2032
9.8.3. Market share analysis, by country, 2022-2032
9.9. Home Care & Self-Testing
9.9.1. Definition, key trends, growth factors, and opportunities
9.9.2. Market size analysis, by region, 2022-2032
9.9.3. Market share analysis, by country, 2022-2032
9.10. Others
9.10.1. Definition, key trends, growth factors, and opportunities
9.10.2. Market size analysis, by region, 2022-2032
9.10.3. Market share analysis, by country, 2022-2032
9.11. Research Dive Exclusive Insights
9.11.1. Market attractiveness
9.11.2. Competition heatmap
10. Point Of Care Testing Market , by Region
10.1. North America
10.1.1. U.S.
10.1.1.1. Market size analysis, by Product Type, 2022-2032
10.1.1.2. Market size analysis, by Platform, 2022-2032
10.1.1.3. Market size analysis, by Mode of Purchase, 2022-2032
10.1.1.4. Market size analysis, by Testing Type, 2022-2032
10.1.1.5. Market size analysis, by End-user, 2022-2032
10.1.2. Canada
10.1.2.1. Market size analysis, by Product Type, 2022-2032
10.1.2.2. Market size analysis, by Platform, 2022-2032
10.1.2.3. Market size analysis, by Mode of Purchase, 2022-2032
10.1.2.4. Market size analysis, by Testing Type, 2022-2032
10.1.2.5. Market size analysis, by End-user, 2022-2032
10.1.3. Mexico
10.1.3.1. Market size analysis, by Product Type, 2022-2032
10.1.3.2. Market size analysis, by Platform, 2022-2032
10.1.3.3. Market size analysis, by Mode of Purchase, 2022-2032
10.1.3.4. Market size analysis, by Testing Type, 2022-2032
10.1.3.5. Market size analysis, by End-user, 2022-2032
10.1.4. Research Dive Exclusive Insights
10.1.4.1. Market attractiveness
10.1.4.2. Competition heatmap
10.2. Europe
10.2.1. Germany
10.2.1.1. Market size analysis, by Product Type, 2022-2032
10.2.1.2. Market size analysis, by Platform, 2022-2032
10.2.1.3. Market size analysis, by Mode of Purchase, 2022-2032
10.2.1.4. Market size analysis, by Testing Type, 2022-2032
10.2.1.5. Market size analysis, by End-user, 2022-2032
10.2.2. UK
10.2.2.1. Market size analysis, by Product Type, 2022-2032
10.2.2.2. Market size analysis, by Platform, 2022-2032
10.2.2.3. Market size analysis, by Mode of Purchase, 2022-2032
10.2.2.4. Market size analysis, by Testing Type, 2022-2032
10.2.2.5. Market size analysis, by End-user, 2022-2032
10.2.3. France
10.2.3.1. Market size analysis, by Product Type, 2022-2032
10.2.3.2. Market size analysis, by Platform, 2022-2032
10.2.3.3. Market size analysis, by Mode of Purchase, 2022-2032
10.2.3.4. Market size analysis, by Testing Type, 2022-2032
10.2.3.5. Market size analysis, by End-user, 2022-2032
10.2.4. Spain
10.2.4.1. Market size analysis, by Product Type, 2022-2032
10.2.4.2. Market size analysis, by Platform, 2022-2032
10.2.4.3. Market size analysis, by Mode of Purchase, 2022-2032
10.2.4.4. Market size analysis, by Testing Type, 2022-2032
10.2.4.5. Market size analysis, by End-user, 2022-2032
10.2.5. Italy
10.2.5.1. Market size analysis, by Product Type, 2022-2032
10.2.5.2. Market size analysis, by Platform, 2022-2032
10.2.5.3. Market size analysis, by Mode of Purchase, 2022-2032
10.2.5.4. Market size analysis, by Testing Type, 2022-2032
10.2.5.5. Market size analysis, by End-user, 2022-2032
10.2.6. Rest of Europe
10.2.6.1. Market size analysis, by Product Type, 2022-2032
10.2.6.2. Market size analysis, by Platform, 2022-2032
10.2.6.3. Market size analysis, by Mode of Purchase, 2022-2032
10.2.6.4. Market size analysis, by Testing Type, 2022-2032
10.2.6.5. Market size analysis, by End-user, 2022-2032
10.2.7. Research Dive Exclusive Insights
10.2.7.1. Market attractiveness
10.2.7.2. Competition heatmap
10.3. Asia-Pacific
10.3.1. China
10.3.1.1. Market size analysis, by Product Type, 2022-2032
10.3.1.2. Market size analysis, by Platform, 2022-2032
10.3.1.3. Market size analysis, by Mode of Purchase, 2022-2032
10.3.1.4. Market size analysis, by Testing Type, 2022-2032
10.3.1.5. Market size analysis, by End-user, 2022-2032
10.3.2. Japan
10.3.2.1. Market size analysis, by Product Type, 2022-2032
10.3.2.2. Market size analysis, by Platform, 2022-2032
10.3.2.3. Market size analysis, by Mode of Purchase, 2022-2032
10.3.2.4. Market size analysis, by Testing Type, 2022-2032
10.3.2.5. Market size analysis, by End-user, 2022-2032
10.3.3. India
10.3.3.1. Market size analysis, by Product Type, 2022-2032
10.3.3.2. Market size analysis, by Platform, 2022-2032
10.3.3.3. Market size analysis, by Mode of Purchase, 2022-2032
10.3.3.4. Market size analysis, by Testing Type, 2022-2032
10.3.3.5. Market size analysis, by End-user, 2022-2032
10.3.4. Australia
10.3.4.1. Market size analysis, by Product Type, 2022-2032
10.3.4.2. Market size analysis, by Platform, 2022-2032
10.3.4.3. Market size analysis, by Mode of Purchase, 2022-2032
10.3.4.4. Market size analysis, by Testing Type, 2022-2032
10.3.4.5. Market size analysis, by End-user, 2022-2032
10.3.5. South Korea
10.3.5.1. Market size analysis, by Product Type, 2022-2032
10.3.5.2. Market size analysis, by Platform, 2022-2032
10.3.5.3. Market size analysis, by Mode of Purchase, 2022-2032
10.3.5.4. Market size analysis, by Testing Type, 2022-2032
10.3.5.5. Market size analysis, by End-user, 2022-2032
10.3.6. Rest of Asia-Pacific
10.3.6.1. Market size analysis, by Product Type, 2022-2032
10.3.6.2. Market size analysis, by Platform, 2022-2032
10.3.6.3. Market size analysis, by Mode of Purchase, 2022-2032
10.3.6.4. Market size analysis, by Testing Type, 2022-2032
10.3.6.5. Market size analysis, by End-user, 2022-2032
10.3.7. Research Dive Exclusive Insights
10.3.7.1. Market attractiveness
10.3.7.2. Competition heatmap
10.4. LAMEA
10.4.1. Brazil
10.4.1.1. Market size analysis, by Product Type, 2022-2032
10.4.1.2. Market size analysis, by Platform, 2022-2032
10.4.1.3. Market size analysis, by Mode of Purchase, 2022-2032
10.4.1.4. Market size analysis, by Testing Type, 2022-2032
10.4.1.5. Market size analysis, by End-user, 2022-2032
10.4.2. UAE
10.4.2.1. Market size analysis, by Product Type, 2022-2032
10.4.2.2. Market size analysis, by Platform, 2022-2032
10.4.2.3. Market size analysis, by Mode of Purchase, 2022-2032
10.4.2.4. Market size analysis, by Testing Type, 2022-2032
10.4.2.5. Market size analysis, by End-user, 2022-2032
10.4.3. Saudi Arabia
10.4.3.1. Market size analysis, by Product Type, 2022-2032
10.4.3.2. Market size analysis, by Platform, 2022-2032
10.4.3.3. Market size analysis, by Mode of Purchase, 2022-2032
10.4.3.4. Market size analysis, by Testing Type, 2022-2032
10.4.3.5. Market size analysis, by End-user, 2022-2032
10.4.4. South Africa
10.4.4.1. Market size analysis, by Product Type, 2022-2032
10.4.4.2. Market size analysis, by Platform, 2022-2032
10.4.4.3. Market size analysis, by Mode of Purchase, 2022-2032
10.4.4.4. Market size analysis, by Testing Type, 2022-2032
10.4.4.5. Market size analysis, by End-user, 2022-2032
10.4.5. Rest of LAMEA
10.4.5.1. Market size analysis, by Product Type, 2022-2032
10.4.5.2. Market size analysis, by Platform, 2022-2032
10.4.5.3. Market size analysis, by Mode of Purchase, 2022-2032
10.4.5.4. Market size analysis, by Testing Type, 2022-2032
10.4.5.5. Market size analysis, by End-user, 2022-2032
10.4.6. Research Dive Exclusive Insights
10.4.6.1. Market attractiveness
10.4.6.2. Competition heatmap
11. Competitive Landscape
11.1. Top winning strategies, 2022
11.1.1. By strategy
11.1.2. By year
11.2. Strategic overview
11.3. Market share analysis, 2022
12. Company Profiles
12.1. Abbott Laboratories
12.1.1. Overview
12.1.2. Business segments
12.1.3. Product portfolio
12.1.4. Financial performance
12.1.5. Recent developments
12.1.6. SWOT analysis
12.2. Roche Diagnostics
12.2.1. Overview
12.2.2. Business segments
12.2.3. Product portfolio
12.2.4. Financial performance
12.2.5. Recent developments
12.2.6. SWOT analysis
12.3. Siemens Healthineers
12.3.1. Overview
12.3.2. Business segments
12.3.3. Product portfolio
12.3.4. Financial performance
12.3.5. Recent developments
12.3.6. SWOT analysis
12.4. Johnson & Johnson
12.4.1. Overview
12.4.2. Business segments
12.4.3. Product portfolio
12.4.4. Financial performance
12.4.5. Recent developments
12.4.6. SWOT analysis
12.5. Danaher Corporation
12.5.1. Overview
12.5.2. Business segments
12.5.3. Product portfolio
12.5.4. Financial performance
12.5.5. Recent developments
12.5.6. SWOT analysis
12.6. Becton
12.6.1. Overview
12.6.2. Business segments
12.6.3. Product portfolio
12.6.4. Financial performance
12.6.5. Recent developments
12.6.6. SWOT analysis
12.7. Dickinson and Company (BD)
12.7.1. Overview
12.7.2. Business segments
12.7.3. Product portfolio
12.7.4. Financial performance
12.7.5. Recent developments
12.7.6. SWOT analysis
12.8. Philips Healthcare
12.8.1. Overview
12.8.2. Business segments
12.8.3. Product portfolio
12.8.4. Financial performance
12.8.5. Recent developments
12.8.6. SWOT analysis
12.9. Sysmex Corporation
12.9.1. Overview
12.9.2. Business segments
12.9.3. Product portfolio
12.9.4. Financial performance
12.9.5. Recent developments
12.9.6. SWOT analysis
12.10. Quidel Corporation
12.10.1. Overview
12.10.2. Business segments
12.10.3. Product portfolio
12.10.4. Financial performance
12.10.5. Recent developments
12.10.6. SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
